Xeris Biopharma Holdings, Inc. has announced the appointment of Menassie Taddese to its Board of Directors, effective November 2, 2026. This decision to expand the Board from eight to nine members underscores the company's commitment to enhancing its leadership and governance as it navigates the competitive landscape of the biopharmaceutical industry.

Menassie Taddese will serve as a Class II director, with his term set to expire at the company's 2029 annual meeting of stockholders. He will also join the Board's Audit Committee, bringing valuable experience from his previous roles in the pharmaceutical sector.

Background

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company based in Chicago, Illinois, specializing in the development and commercialization of innovative medicines for endocrine and rare diseases. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. Xeris is listed on the Nasdaq under the ticker symbol XERS.

What the Filing Says

The SEC filing states, "Effective as of November 2, 2026, the Board of Directors of Xeris Biopharma Holdings, Inc. increased the size of the Board from eight to nine members, thereby creating a vacancy on the Board, and appointed Menassie Taddese to fill such vacancy." Taddese's extensive background includes serving as President, Emerging Markets at Viatris Inc. and various roles at Pfizer Inc.

Impact

Taddese's appointment is expected to positively influence Xeris's strategic direction and governance, particularly as the company advances its clinical pipeline and commercial portfolio. His experience in leading pharmaceutical businesses and overseeing public company governance matters is anticipated to enhance the Board's effectiveness.

What's Next

The filing does not say what happens next.